Zobrazeno 1 - 10
of 20
pro vyhledávání: ''
Autor:
Sepideh Azarianpour, Germán Corredor, Kaustav Bera, Patrick Leo, Pingfu Fu, Paula Toro, Amy Joehlin-Price, Mojgan Mokhtari, Haider Mahdi, Anant Madabhushi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
BackgroundWe present a computational approach (ArcTIL) for quantitative characterization of the architecture of tumor-infiltrating lymphocytes (TILs) and their interplay with cancer cells from digitized H&E-stained histology whole slide images and ev
Autor:
Antony Tin, Lillian L. Siu, Nickolas Attanasio, David P. Goldstein, Tina Shek, Bayardo Perez-Ordonez, J. Javier Díaz-Mejía, Ronald Shazer, Anna Spreafico, Douglas B. Chepeha, Ben X Wang, Ilan Weinreb, Hirak Der-Torossian, Andrew Hope, Aaron R. Hansen, Daniel Vilarim Araujo, Qingyan Au, Amy Prawira, John R. de Almeida, Alexey Aleshin, Jordan Feeney, Marc Oliva, Peter Olson, Stephen M. Smith, Jonathan C. Irish, Jeff Bruce, Anthony Fortuna, Himanshu Sethi, Isan Chen, Trevor J. Pugh, Dax Torti, Scott V. Bratman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundSitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic ant
Autor:
Sonali Jindal, Hong Chen, Christopher J. Logothetis, Ana Aparicio, Rebecca S. S. Tidwell, Paul G. Corn, Padmanee Sharma, Bilal A. Siddiqui, Ashwin Varma, James P. Allison, Sumit K. Subudhi, Shalini S. Yadav, Sreyashi Basu
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
BackgroundImmune checkpoint therapy (ICT) has low response rates in patients with metastatic castration-resistant prostate cancer (mCRPC), in part due to few T cells in the tumor microenvironment (TME). Anti-cytotoxic T lymphocyte-associated protein
Autor:
Eirini Pectasides, Sarah Derks, Charles S. Fuchs, Megan E. Cavanaugh, Peter C. Enzinger, Anuj K. Patel, Amanda J. Rode, Douglas A. Rubinson, Adam J. Bass, Bridget Fitzpatrick, Lauren K. Brais, Nadine Jackson McCleary, Mariano Severgnini, Patrick H. Lizotte, Fahire G Akarca, Jeffrey W. Clark, Leonie K. de Klerk, Melissa G Jean, Matthew Nazzaro, Jeremy Augustin, Mohamed Uduman, James M. Cleary, Hui Zheng, Nihal Raman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
BackgroundImmune checkpoint inhibitors have revolutionized cancer treatment, but the benefits in refractory patients with esophageal cancer have been modest. Predictors of response as well as new targets for novel therapeutic combinations are needed.
Autor:
Eleanor Y. Chen, Bonnie LaFleur, Jose G. Mantilla, Brett Schroeder, Marissa Vignali, Shihong Zhang, Seth M. Pollack, Michael J. Wagner, Laura Riolobos, Brian C Schulte, Robert H. Pierce, Kevin C Flanagan, Kimberly S. Smythe, Julie Rytlewski, Lee D. Cranmer, Robin L. Jones, Natalie A. LaFranzo, Teresa S. Kim, Jean S. Campbell, Rachel M. Gittelman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundDedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the observation of clinical responses to PD-1 inhibitors, little is known about the imm
Autor:
Na Huang, Jianjun Peng, Jiani Wu, Nailin Li, Li Sun, Zilan Ye, Huiying Sun, Yunfang Yu, Jianhua Wu, Jianping Bin, Yong Li, Min Shi, Kyoung-Mee Kim, Xiaoxiang Rong, Jian Xiao, Wangjun Liao, Wenjun Qiu, Rui Zhou, Yulin Liao, Dongqiang Zeng, Gaofeng Wang, Huiyan Luo, Yichen Xue
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundDurable efficacy of immune checkpoint blockade (ICB) occurred in a small number of patients with metastatic gastric cancer (mGC) and the determinant biomarker of response to ICB remains unclear.MethodsWe developed an open-source TMEscore R
Autor:
Wenli Cai, Jian Huang, Qiong Wang, Kewei Xu, Xiangyu Zhan, Kai Yao, Qianghua Zhou, Kaiwen Li, Wei Yao, Xingxing Zang, Hai Huang, Shirong Peng, Yiming Lai
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
BackgroundAlthough immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers, exhibit prominent antitumor effects against numerous malignancies, their benefit for patients w
Autor:
Peixin Chen, Chunyan Wu, Minlin Jiang, Yi Xu, Liping Zhang, Jun Zhu, Chenglong Sun, Yayi He, Jia Yu, Caicun Zhou, Shengyu Wu, Hao Wang, Qiyu Fang, Hui Sun, Wencheng Zhao, Zixuan Zheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundImmunotherapies may prolong the survival of patients with small-cell lung cancer (SCLC) to some extent. The role of forkhead box protein P3 (FOXP3) in tumor microenvironment (TME) remains controversial. We aimed to examine FOXP3-related exp
Autor:
Sharon Ng, Meenal Sinha, Rahul Aggarwal, Terence W. Friedlander, Christopher Nguyen, Li Zhang, Sumit K. Subudhi, Brandon Chen, E Liu, Alexander Cheung, Padmanee Sharma, Kate Allaire, James P. Allison, Lawrence Fong, Matthew H. Spitzer, Eric J. Small, Jaqueline Marquez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 5
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 5
BackgroundSipuleucel-T is a US Food and Drug Administration-approved autologous cellular immunotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We examined whether administering ipilimumab after
Autor:
Angen Liu, Robert L. Ferris, Dan P. Zandberg, Ashley V. Menk, Maria A. Velez, Greg M. Delgoffe, Kristin DePeaux, Daniel P. Normolle
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
The majority of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (HNSCC) (R/M) do not benefit from anti-PD-1 therapy. Hypoxia induced immunosuppression may be a barrier to immunotherapy. Therefore, we examined the metab